BioXcel Therapeutics, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
BioXcel Therapeutics, Inc. (BTAI) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $56.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2026-08-13
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2026-03-31 was $56.00K, a 29.11% decline year-over-year.
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-12-31 was $84.00K, a 6.33% increase year-over-year.
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2025-09-30 was $82.00K, a 6.49% increase year-over-year.
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2025 was $326.00K, a 6.54% increase from fiscal 2024.
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2024 was $306.00K, a 6.25% increase from fiscal 2023.
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2023 was $288.00K, a 6.27% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2022 was $271.00K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $56.00K 10-Q · filed 2026-08-13 | $140.00K derived: sum of 3 quarters · filed 2026-08-13 | $222.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $56.00K 10-Q · filed 2026-05-15 | $140.00K derived: sum of 2 quarters · filed 2026-05-15 | $222.00K derived: sum of 3 quarters · filed 2026-05-15 | $303.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $84.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $166.00K derived: sum of 2 quarters · filed 2026-03-27 | $247.00K derived: sum of 3 quarters · filed 2026-08-13 | $326.00K 10-K · filed 2026-03-27 |
| 2025-09-30 | $82.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $163.00K derived: sum of 2 quarters · filed 2026-08-13 | $242.00K 10-Q · filed 2025-11-12 | $321.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $81.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $160.00K 10-Q · filed 2026-08-13 | $239.00K derived: sum of 3 quarters · filed 2026-08-13 | $316.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $79.00K 10-Q · filed 2026-05-15 | $158.00K derived: sum of 2 quarters · filed 2026-05-15 | $235.00K derived: sum of 3 quarters · filed 2026-05-15 | $310.00K derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $156.00K derived: sum of 2 quarters · filed 2026-03-27 | $231.00K derived: sum of 3 quarters · filed 2026-03-27 | $306.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $152.00K derived: sum of 2 quarters · filed 2025-11-12 | $227.00K 10-Q · filed 2025-11-12 | $301.00K derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $150.00K 10-Q · filed 2025-08-12 | $224.00K derived: sum of 3 quarters · filed 2025-08-12 | $296.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $75.00K 10-Q · filed 2025-05-12 | $149.00K derived: sum of 2 quarters · filed 2025-05-12 | $221.00K derived: sum of 3 quarters · filed 2025-05-12 | $293.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $146.00K derived: sum of 2 quarters · filed 2025-03-28 | $218.00K derived: sum of 3 quarters · filed 2025-03-28 | $288.00K 10-K · filed 2025-03-28 |
| 2023-09-30 | $72.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $144.00K derived: sum of 2 quarters · filed 2024-11-14 | $214.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | $72.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $142.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | $70.00K 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | $271.00K 10-K · filed 2024-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |